Latest Content

Orforglipron added to titrated insulin glargine reduced HbA1c at 40 weeks while producing clinically meaningful weight reductions.

Despite increases in influenza vaccine rates before the pandemic in the Bronx, rates have decreased between 2020 and 2023.

GLP-1 medications in psoriasis show skin and inflammation gains beyond weight loss; early data in psoriatic arthritis lag as trials ramp up.

The dual glucagon/GLP-1 receptor agonist is also being studied in the SYNCHRONIZE-2, SYNCHRONIZE-CVOT, LIVERAGE, and LIVERAGE-Cirrhosis trials.

Real-world diabetic macular edema care lags trials as fewer VEGF injections and step therapy limit outcomes.

A total of 2288 cases of measles were confirmed in the US for the full year of 2025, suggesting that the cases are set to double in 2026.

Learn how payer fee schedules impact practices, curb administrative costs in healthcare, and boost revenue with audits, tech, and smarter contracts.

The authors evaluated changes in persistence to basal insulin in a Medicare Advantage population in the first year of the Medicare insulin out-of-pocket cost cap.

Remote therapeutic monitoring (RTM) with ePROs powered by AI cuts hospitalizations and boosts therapy time—now a key oncology leader promotes guideliens and reimbursement to make it standard of care.